Personalizing therapy for metastatic breast cancer Journal Article
| Authors: | Morris, P. G.; Hudis, C. A. |
| Article Title: | Personalizing therapy for metastatic breast cancer |
| Abstract: | Treatments for metastatic breast cancer are increasingly tailored towards individual tumor biology. For tumors that overexpress HER2, progressing on trastuzumab and lapatinib, a range of active agents including pertuzumab, neratinib and trastuzumab-MCC-DM1, have demonstrated activity when combined with trastuzumab. In HER2-normal metastatic breast cancer, recent studies suggest that the addition of bevacizumab to first-line chemotherapy improves progression-free survival irrespective of choice of cytotoxic agent. Another interesting area of investigation is the inhibition of poly-ADP-ribose polymerase, an enzyme important for DNA repair. This strategy may be particularly effective in patients with inherited defects in DNA repair or by the co-administration of DNA damaging cytotoxic chemotherapy. This article covers key new areas of systemic therapy for MBC from the American Society of Clinical Oncology 2009 annual meeting. © 2009 Expert Reviews Ltd. |
| Keywords: | cancer survival; protein expression; disease-free survival; unclassified drug; clinical trial; drug tolerability; bevacizumab; cancer combination chemotherapy; dose response; drug dose comparison; drug efficacy; monotherapy; nonhuman; systemic therapy; antineoplastic agents; conference paper; capecitabine; gemcitabine; paclitaxel; antineoplastic agent; carboplatin; low drug dose; progression free survival; thrombocytopenia; epidermal growth factor receptor 2; antineoplastic activity; breast neoplasms; cancer resistance; docetaxel; loading drug dose; drug delivery systems; neoplasm metastasis; heat shock protein 90 inhibitor; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; receptor, erbb-2; taxane derivative; anthracycline derivative; trastuzumab; breast metastasis; metastatic breast cancer; lapatinib; trastuzumab-mcc-dm1; neratinib; parp-inhibitor; pertuzumab; poly-adp ribose polymerase; bsi 201; olaparib; trastuzumab mcc dm1 |
| Journal Title: | Expert Review of Anticancer Therapy |
| Volume: | 9 |
| Issue: | 9 |
| ISSN: | 1473-7140 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2009-01-01 |
| Start Page: | 1223 |
| End Page: | 1226 |
| Language: | English |
| DOI: | 10.1586/era.09.89 |
| PUBMED: | 19761426 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 1" - "Export Date: 30 November 2010" - "CODEN: ERATB" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work